Monday, April 26, 2010
According to Chennai-based diabetologist V. Mohan, India has 50 million people with diabetes and there are another 50 million in the pre-diabetes stage. "It is estimated that the country will have 87 million people with diabetes by the year 2030. India, therefore, has a huge problem of diabetes but the number of professionals to treat diabetes are still less." The spread of diabetes is no longer confined to urban areas, with their unhealthy lifestyles and eating habits, but is fanning out into the rural areas.
Awareness of the disease, and what causes it, is also limited. Pierre Chancel, senior vice-president at the French pharmaceutical company Sanofi-Aventisfor for global diabetes, observes, "Firstly, diagnosis in India is still low. We will work to increase awareness and educate people about diabetes, so the number of patients under treatment will increase." Sanofi-Aventis is the market leader in the Rs 1,400-crore Indian anti-diabetic market, and one of its best-selling drugs is Amaryl.
Among new treatments for diabetes in India are the Exenatide (Byetta) injection, new oral drugs, inhaled insulin, Generex Oral-lyn(TM) insulin spray, Stem cell therapy, Pancreas/Islet cells transplants, and Biocon's oral insulin drug IN-105.